Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk.

ABSTRACT:

Background

Although statins have been shown to reduce the risk of cardiovascular events in patients at low cardiovascular risk, their absolute benefit is small in the short term, which may adversely affect cost-effectiveness. We sought to determine the long-term cost-effectiveness (beyond the duration of clinical trials) of low- and high-potency statins in patients at low cardiovascular risk and to estimate the impact on Canada's publicly funded health care system.

Methods

Using Markov modelling, we performed a cost-utility analysis in which we compared low-potency statins (fluvastatin, lovastatin, pravastatin and simvastatin) and high-potency statins (atorvastatin and rosuvastatin) with no statins in a simulated cohort of low-risk patients over a lifetime horizon. Model out

SUBMITTER: Conly J 

PROVIDER: S-EPMC3216439 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature